Feasibility Study of the Role of Stereotactic Body Radiation Therapy for the Treatment of Early Stage Breast Cancer
Most women with early breast cancer are treated with breast conserving therapy (BCT),
consisting of breast conserving surgery (surgery to remove the cancer itself) followed by
radiation to the breast. This treatment can take time and is associated with its own side
effect profile. An innovative radiation technique called stereotactic body radiation therapy
(SBRT) can deliver large doses of radiation precisely to the tumour while avoiding critical
organs, therefore destroying the cancer and avoiding surgery altogether. SBRT has been
successfully used for a number of cancers and it is proposed that it could be used to
eradicate breast cancer. This feasibility study will investigate the feasibility and safety
of treatment using SBRT in women with early stage breast cancer.
Thirty-two women age 70 years or older with early breast cancer will be treated with SBRT (5
treatments) followed by breast conserving surgery and hormonal therapy. An MRI and breast
conserving surgery will be performed at 8-12 weeks after radiation to assess response to
treatment. The primary outcome of the study will be feasibility, meaning the ability to
deliver radiation treatment as planned. Secondary outcomes will include treatment related
toxicity and pathological response.
If this study shows that SBRT can be used to treat patients primarily, it will lead to
further evaluation of SBRT for early breast cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society